Commercial & Medical Affairs - software & AI news

Daily news on software, AI, and companies shaping commercial & medical affairs.

Showing 39 results
A minimalist illustration of a cloud and data stream representing AI in life sciences.

May 18, 2026

Anthill Cloud - an AI-Powered Content Excellence Platform for the US Life Sciences Market

Anthill has launched Anthill Cloud™, an innovative platform designed to enhance content creation and engagement in the US life sciences sector, particularly for pharmaceutical and biotech companies.The Anthill Cloud™ platform integrates generative AI, modular content authoring, and HCP (Healthcare Professional) engagement into a single, compliant ecosystem. This strategic tool addresses the growing complexity faced by US life science teams, such as the demand for personalized communications, the
Flat illustration of pharmaceutical promotional materials and structured data

May 18, 2026

Shaman Launches Shaman Atlas to Convert Pharma's Approved Content Into Structured Data

Shaman has introduced Shaman Atlas, a groundbreaking AI-driven tool designed to transform pharmaceutical promotional materials into structured, reusable data.This innovative solution addresses a significant challenge faced by large pharmaceutical companies, which typically manage over 400,000 approved promotional files. These files often contain crucial information, such as validated claims and regulatory content, but are locked in flat formats that hinder effective extraction and reuse. Shaman
A minimalist cloud icon symbolizing cloud computing in life sciences.

May 17, 2026

Veeva Systems stock (US9224171002): earnings spotlight and cloud strategy for life sciences

Veeva Systems has recently shared its quarterly results and updated forecasts, capturing investor interest in the life sciences sector.Veeva Systems, a key player in cloud software for the life sciences industry, has reported its fiscal fourth quarter and full-year results, alongside an updated outlook for fiscal 2026. The company's stock reacted positively on the NYSE following the announcement, which highlighted significant revenue growth and profitability trends. For the fiscal year 2025, Vee
A clipboard and notepad in a pharmaceutical office setting

May 15, 2026

Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success

Virtual Science AI has introduced Medical Competitor AI, a pioneering platform designed to enhance the success of pharmaceutical asset launches by tracking competitor activities and scientific narratives.This innovative AI-driven platform stands out in the life sciences sector by providing comprehensive insights into competitor medical activities, including conference participation, social media engagement, and publication trends. Traditionally, such analyses have been labor-intensive and often
A drug compound vial on a lab bench with research papers in the background.

May 15, 2026

EQS-News: Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success - boerse.de

Virtual Science AI has unveiled Medical Competitor AI, a pioneering platform designed to track competitor activities and scientific narratives in the pharmaceutical industry. This innovative tool aims to enhance the success of new drug launches by providing real-time insights into competitors' actions and strategies.The Medical Competitor AI platform enables pharmaceutical teams to analyze various aspects of competitor engagement, including conference presentations, social media interactions, an
A minimalist dollar sign representing pharmaceutical marketing finances.

May 14, 2026

Why 75 Top Pharma Execs Are Ditching Fragmented Marketing Stacks

A coalition of 75 pharmaceutical executives has rallied behind a new marketing operations platform, emphasizing the urgent need for streamlined commercial technology in the life sciences sector. This initiative, revealed at the Doceree Health Decode: The Makers Summit 2026 in New York, seeks to address the inefficiencies caused by fragmented marketing systems.The executives, representing companies like Sanofi and Bristol Myers Squibb, collectively manage over $40 billion in annual brand spending
A test tube with a colorful liquid sample on a lab bench

May 14, 2026

BranchLab Lands $26 Million in Series A

BranchLab, an AI platform focused on pharmaceutical commercialization, has successfully secured $26 million in Series A funding, increasing its total funding to $35 million.This funding round was led by McKesson Ventures, which is known for investing in healthcare technology aimed at enhancing the efficiency and quality of healthcare delivery. Other notable investors included FCA Venture Partners, Sanofi Ventures, and AIX Ventures, indicating a strong interest in innovative solutions within the
A test tube in a laboratory setting

May 14, 2026

BranchLab: $26 Million Series A Raised To Expand AI Platform For Pharma Commercialization

BranchLab has successfully secured $26 million in Series A funding, spearheaded by McKesson Ventures, with additional contributions from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. This funding boosts the company's total to $35 million, aimed at enhancing its AI platform for pharmaceutical commercialization.The platform seeks to revolutionize pharmaceutical commercialization processes by streamlining patient identification, audience segmentation, and performance measurement in real
A syringe and vial in a clinical lab setting

May 14, 2026

SwishX Launches Agentic AI Platform for Pharma and MedTech Industry

SwishX has launched an innovative Agentic AI platform aimed at transforming the pharmaceutical and medtech industries. This Bengaluru-based startup seeks to enhance sales, marketing, and distribution by leveraging advanced artificial intelligence technologies. With a target of securing over 100 enterprise clients and achieving $5 million in annual recurring revenue by FY 2026–27, SwishX is also planning to expand its reach into emerging markets such as Latin America, Southeast Asia, and Africa.T
A minimalist illustration of a pill bottle and gear symbolizing pharmaceutical automation.

May 14, 2026

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

Dushyant Sapre, the Founder and CEO of SwishX, asserts that AI is poised to revolutionize the pharmaceutical industry by automating a significant portion of commercial processes, potentially eliminating 70-80% of them in the next decade. This perspective arises from the unique challenges faced by India's pharma sector, particularly in the realm of generic drug distribution, where operational efficiency is paramount.SwishX positions itself as an AI-native operating system tailored for pharma sale
A syringe and ampoule on a laboratory shelf in soft lighting

May 14, 2026

SwishX Launches Agentic AI Platform for Pharma & Medtech, Raises $2.2 Mn Seed Funding

SwishX has introduced its Agentic AI platform tailored for the pharmaceutical and medtech sectors, alongside securing $2.2 million in seed funding from various investors.The Bengaluru-based startup, founded by former executives from Google and Amazon, aims to achieve $5 million in annual recurring revenue and onboard over 100 enterprise clients by FY 2026–27. The company is set to expand its reach into emerging markets, including regions in Latin America, Southeast Asia, the Middle East, Africa,
A syringe filled with a pharmaceutical compound in a dimly lit lab setting.

May 13, 2026

SwishX Launches Agentic AI Platform For Pharma

SwishX has launched an innovative Agentic AI platform tailored for the pharmaceutical and medtech sectors, aiming to revolutionize sales and marketing processes through advanced artificial intelligence.Based in Bengaluru, SwishX is targeting a contracted annual recurring revenue of $5 million and plans to acquire over 100 enterprise clients by the end of the fiscal year 2026-27. The startup has recently secured $2.2 million in seed funding to support its expansion into various emerging markets,